As­traZeneca jet­ti­sons an­oth­er drug, this time grab­bing $30M for out-li­cens­ing deal

Add one more drug to As­traZeneca’s grow­ing pile of pipeline drugs it’s jet­ti­son­ing. This time, the deal fo­cus­es on an ear­ly-stage res­pi­ra­to­ry drug dubbed AZD7986 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA